AbbVie Inc. (LON:0QCV)

Market Cap	287.30B +16.1%
Revenue (ttm)	44.37B +7.4%
Net Income	1.75B -53.4%
EPS	0.98 -54.0%
Shares Out	n/a
PE Ratio	164.47
Forward PE	16.97
Dividend	4.98 (2.24%)
Ex-Dividend Date	Jan 16, 2026

Volume	5,272
Average Volume	22,230
Open	220.50
Previous Close	222.99
Day's Range	219.00 - 222.35
52-Week Range	164.50 - 244.49
Beta	0.35
RSI	50.97
Earnings Date	Feb 4, 2026

About AbbVie

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 2012
• Employees: 55,000
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0QCV

Financial Performance

In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.

Financial numbers in USD